Marshall microbrewery to kick off new MEDCO program targeting empty buildings
A new microbrewery is the first to be funding through a Marshall Economic Development Corporation program that seeks to get empty, blighted buildings occupied.
Marshall City Councilmembers unanimously approved funds for the Marshall Economic Development Corporation’s first project funded through the new Certificate of Occupancy Grant Program during Thursday’s regular city council meeting.
Director Rush Harris presented on the new program, and the planned project, during the meeting.
“We have another interesting project here, and this isn’t what you are used to seeing from me,” Harris said during the meeting.
The project is for the creation of a new microbrewery, restaurant and pub at 108 W. Houston by the Rueggenbach Brewing Company, which Harris said is owned by a Marshall native.
He explained that the owner has a plan to turn the blighted structure into a taxable business, and through this has been working with MEDCO and applying through the organization’s new Certificate of Occupancy Grant Program for funding assistance.
Due to the current state of the building, construction costs to get the building up to code and receive a certificate of occupancy are expected to be over $1.2 million.
Harris said that the structure has been determined to be blight by the Marshall EDC Board of Directors and an economic or social liability to the municipality.
This, Harris said, made the project the perfect candidate for MEDCO’s new CO grant program, which offers a reimbursement grant of up to $100,000 or 10 percent of construction costs and site improvements needed to receive an official CO from the City of Marshall.
”…In this cross-sectional study of unvaccinated US adults, antibodies were detected in  99% of individuals who reported a positive COVID-19 test result,  in 55% who believed they had COVID-19 but were never tested, and  in 11% who believed they had never had COVID-19 infection…
Anti-RBD levels were observed after a positive COVID-19 test result up to 20 months, extending previous 6-month durability data…Although evidence of natural immunity in unvaccinated healthy US adults up to 20 months after confirmed COVID-19 infection is encouraging, it is unclear how these antibody levels correlate with protection against future SARS-CoV-2 infections, particularly with emerging variants. The public health implications and long-term understanding of these findings merit further consideration.”
”…Findings In this cross-sectional study that included 2383 patients with violent injuries, there was a significant increase in patients who presented with firearm injuries but not stabbing injuries during the first pandemic year compared with the previous 5 years. This surge in firearm injuries began while Massachusetts was still under a stay-at-home advisory and before large-scale racial justice protests….These findings suggest that unprecedented measures implemented to mitigate the spread of COVID-19 were associated with an increase in gun violence. As the pandemic abates, efforts at community violence prevention and intervention must be redoubled to defend communities against the epidemic of violence…”
(J. Harris: I didn’t look at this editorial when it was first printed some five days ago, but I have subsequently found the 11 min. read to be largely non-political and accurate historically and factually. I’ve now read it 3 times and find little with which to disagree.)
”…It’s easy to speak as if policy smoothly reshapes reality…. But policy lies downstream of society. Mandates are not self-executing; to work, policies need to be followed, guidance needs to be believed. Public health is rooted in the soil of trust. That soil has thinned in America…You know what’s better than a vaccine mandate? A society that doesn’t need one…When it comes to deaths caused by infections, no single variable explains everything, or even all that much, with the exception of age. The coronavirus strikes the old with particular viciousness, and so the age of a population explains 47 percent of the variation in fatality ratios between countries. This helps explain why richer countries have seen a disproportionate number of deaths: Richer countries are older…Moving every country to the 75th percentile of trust in their fellow citizens — roughly South Korea’s level — would have prevented 40 percent of global infections…”
”…The Japanese government…understood that the virus was airborne, and they made sure their citizenry knew it. The message became that “People should avoid the three C’s, which are closed spaces, crowded places and close-contact settings. The Japanese government shared this advice with the public in early March, and it became omnipresent. The message to avoid the three C’s was on the news, variety shows, social media and posters. ‘Three C’s’ was even declared the buzzword of the year in Japan in 2020…”
SOME MORE ABOUT DEER FROM HOPKINS
WHITE-TAILED DEER White-tailed deer infected with SARS-CoV-2 have been identified in at least 15 US states—Arkansas, Illinois, Iowa, Kansas, Maine, Massachusetts, Minnesota, New Jersey, New York, North Carolina, Ohio, Oklahoma, Pennsylvania, Tennessee, and Virginia—adding to concerns that the wild animals could become a potential source of new variants. Researchers looking at deer in Iowa found 1,200 of 2,000 lymph node samples collected from deer that were killed by hunters or car strikes tested positive for the virus. Additionally, white-tailed deer on Staten Island, New York, have been found to be carrying the Omicron variant, the first time the variant has been detected in wild animals. Researchers say it is likely deer are being infected through human contact, then spreading the virus to other deer, and so far there is no evidence that the animals have transmitted the virus back to humans. But more widespread infection among the estimated 30 million deer in the US raises the risk that the animals could become a viral reservoir, which could lead to spillover into humans or other animal species. NEW ENGLAND JOURNAL OF MEDICINE:The Patchwork U.S. Public Health System + Public Health Audio(click link below at end of this mailout)8 MINUTE AUDIO REGARDING NEEDS OF PUBLIC HEALTH “SYSTEM”Final Analysis of Efficacy and Safety of Single-Dose Ad26.COV2.S (JOHNSON AND JOHNSON)”…Overall, our findings indicate that a single dose of Ad26.COV2.S provided protection against severe disease and hospitalization, which could be important in regions requiring mass vaccination or in populations with poor adherence to two-dose prime regimens, and support the use of Ad26.COV2.S in the ongoing effort against the global Covid-19 pandemic….the efficacy of Ad26.COV2.S against moderate to severe–critical disease and against severe–critical disease was lower than that observed in clinical trials assessing messenger RNA vaccines.23,24 The recently noted incidence of breakthrough infections with the omicron variant in vaccine-primed persons,25 regardless of the primary vaccine regimen, suggests that a booster may be required for all primary vaccine regimens.(J. Harris: So J&J will be relegated to use in less civilized areas — if its manufacture is continued. It is most certainly better than no vaccination at all, and updates and boosters would be helpful.) From Hopkins: More on J&JJ&J-JANSSEN VACCINE PRODUCTION Johnson & Johnson (J&J) late last year temporary halted production of its SARS-CoV-2 vaccine at the only plant making usable batches of the shots, a facility run by J&J subsidiary Janssen in the Netherlands capable of manufacturing more than 50 million doses per month, according to a report in The New York Times. The single-dose vaccine, which does not need ultra-cold storage, is the first choice for many low- and middle-income countries (LMICs), and the move caught officials with the African Union and the COVAX initiative off guard when they learned about the production suspension from Times reporters. The facility where the vaccine was being produced is instead manufacturing an experimental vaccine against a different virus, which some noted could be a more profitable venture. A J&J representative said the company has millions of finished doses in inventory, continues to deliver vaccine to fill-and-finish facilities, and intends to deliver on its vaccine commitments to LMICs. Notably, the company failed to deliver on commitments made to COVAX last May. Last year, J&J ran into regulatory problems with Maryland-based contractor Emergent BioSolutions when it did not pass US FDA inspections. The Emergent facility continues to require FDA review of vaccine batches manufactured at the plant, and none have been cleared for distribution. J&J has plans to produce SARS-CoV-2 vaccine at 2 other plants, one in the US and another in India, but those facilities are not expected to be operational until late spring. The Dutch production plant is expected to begin producing the J&J-Janssen vaccine again next month, although those doses will not be shipped until May or June. AND LAST BUT NOT LEASED:DISCLAIMERThe information contained in this electronic message is neither proprietary nor confidential and is not intended only for the use of the individual or entity named above. Further, in addition to being hot to the touch – is likely dangerous to your comfort. WHY ARE YOU READING THIS? If you are not the intended recipient, or the employee or agent responsible for delivering this message to the intended recipient, you are hereby notified that your luck may have just changed. Dissemination, distribution or copying of this communication is compulsory. If you have received this message in error, consider immediately adopting a new religion or world-view and promptly notify someone (anyone) that e-mail disclaimers are not only more useless than junk mail, they are clear proof that the legal profession can con people into doing just about anything
GIVE US YOUR FEEDBACK. CLICK ON “COMMENT” TO TELL US WHAT YOU THINK or use one of the alternative methods for providing feedback.